Customers for Life?

Customers for Life?

Up next

The Old Software Moat Is Dead — How to Spot the Enterprise AI Companies That Are Actually Winning

Most companies say they're doing AI. A surprising number are doing very little — and a Chief AI Officer at one of the world's largest automation platforms has the receipts to prove it. Motley Fool analyst Rachel Warren talks with Adam Field, Chief AI Officer at Tungsten Automatio ...  Show more

The Truth About Spending in Retirement and Why It’s Good News

Knowing how much income you’ll need in retirement is a key variable in determining how much you need to have saved before you stop working. But what many people believe about how spending progresses over the course of retirement is wrong. Host Robert Brokamp speaks with David Bla ...  Show more

Recommended Episodes

The business of not dying
Business Daily

Is longevity the next growth industry? We look at why billionaires are betting on 'rejuvenation' tech and whether any of this could help more of us live beyond 100. We meet the entrepreneurs selling 'superfoods', personalised health plans, and longevity consulting, hoping to cash ...  Show more

The $100 billion opportunity: How anti-obesity drugs are reshaping healthcare and consumer behavior
Exchanges

Goldman Sachs Research’s Chris Shibutani and Jason English explain the business and investor implications of the latest anti-obesity medications and their ripple effects in the healthcare industry and beyond. Learn more about your ad choices. Visit megaphone.fm/adchoices 

Reach Customers, Spend Less With These Expert Tips
Shopify Masters

The marketing landscape is ever changing. Digital advertising costs are rising and there are more restrictions to access customer data. How can businesses navigate these realities and reach their business goals? 

Eric Seufert, founder and partner at Heracles Capital, and ...

  Show more

Different Reads On The Consumer… And Pharma’s Obesity Drug Price Negotiations 11/5/25
CNBC's "Fast Money"

Earnings are filtering in, and companies are seeing a tale of two very different consumers. The group raising concerns about their customer base, and the names not seeing any slowdown. Plus Novo and Eli Lilly nearing a deal with the White house to lower obesity drug prices. Wh ...

  Show more